Briana Contreras

The rationale for treating metastatic breast cancer with a dual HER2-targeted therapy approach.

Briana Contreras, associate editor of MHE, spoke with Edmundo Gonzalez, CEO of Marpai Health, for this week's episode of Tuning In to the C-Suite podcast. The two talked about the significance of AI and deep learning in healthcare and how they will benefit the self-insurance market.

In this part three video series, Civica Rx CEO Martin VanTrieste says Civica is launching an outpatient retail market with its first retail drug coming to the market next year.

Ian E Krop, MD, PhD, elaborates on which treatment settings are most appropriate to use HER2-targeted therapies in to manage metastatic breast cancer.

Considerations regarding how to best integrate newer targeted therapies available for HER2-positive metastatic breast cancer [MBC] into clinical practice.

Editors of MHE and their furry friends had the pleasure of speaking with Dr. Glenn Levine, professor of medicine at Baylor College of Medicine and chief of the cardiology section at Michael E. DeBakey VA Medical Center in Houston. Dr. Levine is also a volunteer medical expert for the American Heart Association’s Healthy Bond for Life initiative and is lead author of the Association’s Scientific Statement on Pet Ownership and Cardiovascular Risk. In the conversation, Dr. Levine shared some wellbeing tips on how our pets can benefit our mental and physical health and wellbeing.

Civica Rx CEO Martin VanTrieste says Civica’s members are experiencing fewer shortages because of strategies used by the company.

Civica Rx is using long-term contracts and payment on delivery as a way to keep manufacturers in the market, Civica Rx CEO and president Martin VanTrieste said in an interview with MHE.

Glaucoma affects many people across the globe, but primarily, it's affecting African Americans due to access.

Briana Contreras, associate editor of Managed Healthcare Executive, spoke with Mark Poling, chief product officer of Zipari, a health insurance tech organization, about how a direct-to-consumer model can simplify the enrollment process. He also shared the benefits the model has to health insurance systems’ operations.

Ian E. Krop, MD, PhD, of Dana-Faber Cancer Institute, highlights more recent targeted therapy approvals for HER2-positive metastatic breast cancer and describes how each therapy is designed to work.

Frontline therapies available for newly diagnosed HER2-positive metastatic breast cancer and variables that impact treatment selection.

In this week's episode Senior Editor Peter Wehrwein chats with Founder and Executive Chairwoman of Caravan Health Lynn Barr. The two discussed the relationship of payers and ACOs and the approach toward the direct contracting model.

Biden is proposing a $46 million increase to the Ryan White HIV/AIDS Programs and $20 million for HUD’s Housing Opportunities for Persons with AIDS program. However, no increases were planned for hepatitis programs.

In this week’s episode of Tuning In to the C-Suite podcast, MHE Associate Editor Briana Contreras spoke with Ash Shehata, KPMG’s national sector leader for healthcare & life sciences. The two chatted about a recent paper by KPMG titled “From payor to healthcare partner,” which highlights how the pandemic drove changes for plans to adopt a patient-centric model and it gives a look into the six healthcare trends to watch for in 2021.

Paul K. Paik, MD, considers the future of MET-directed therapies in non-small cell lung cancer.

Paul K. Paik, MD, discusses how the results of the VISION trial and the recent FDA approval of tepotinib will impact clinical practice.

An expert in non-small cell lung cancer discusses the key efficacy and safety findings from the VISION trial of tepotinib in patients with NSCLC and MET exon 14 skipping alterations.

A key opinion leader thoracic oncology reviews the clinical significance of MET exon 14 skipping in NSCLC as well as recent advances in MET-directed therapy.

Paul K. Paik, MD, discusses currently available targeted therapies for patients with NSCLC.

Briana Contreras, associate editor of Managed Healthcare Executive, spoke with Chris Evanguelidi, head of healthcare at Redpoint Global, about the best practices for closing the healthcare experience gap and devising an effective patient engagement strategy through a more patient-centric health system.

An expert in non-small cell lung cancer describes targetable gene alterations and how these impact treatment selection.

Managed Healthcare Executive's Senior Editor, Peter Wehrwein, and Associate Editor, Briana Contreras, spoke with MHE Editorial Advisory Board Member Lili Brillstein for a new episode of the "Meet the Board" series on "Tuning In to the C-Suite" podcast. Lili is CEO of BCollaborative, which works with stakeholders across the healthcare continuum to successfully make the move from fee for service to value-based healthcare. In this episode we get to learn a bit more about Lili's career and hear her thoughts on the advancements of episodes of care, as well as the challenges of transitioning from fee-for-service to value-based care during COVID-19.

Hang up the masks, Dr. Sachin Nagrani, medical director of telemedicine/home doctor visit service Heal, says there is light at the end of the tunnel for public health and those newly infected by COVID.

Two of the biggest issues in healthcare, currently, are the lack of communication between prescribers and pharmacists, and the number of factors that prevent healthcare professionals from offering patient-centric services.

Briana Contreras, associate editor of Managed Healthcare Executive, speaks with Chris Evanguelidi, head of healthcare at Redpoint Global, for this week's episode of "Tuning In to the C-Suite" podcast. In this conversation, the two discussed the best practices for closing the healthcare experience gap and devising an effective patient engagement strategy through a more patient-centric health system.

Paul K. Paik, MD, reviews the importance of biomarker testing and best practices in testing in patients with non-small cell lung cancer.

In this final part of a two-part video series, Briana Contreras, associate editor of Managed Healthcare Executive spoke with Dr. Sheldon Fields Associate Dean for Equity Inclusion and Research Professor in the College of Nursing at Penn State University, about the ongoing All of Us research program. All of Us is an initiative through partners of the National Black Nurses Association, which Fields is vice president of, and the National Institutes of Health that invites one million people across the U.S. to help build one of the most diverse health databases in U.S. history.

In this first of a two-part video series, Briana Contreras, associate editor of Managed Healthcare Executive spoke with Dr. Sheldon Fields Associate Dean for Equity Inclusion and Research Professor in the College of Nursing at Penn State University, about the ongoing All of Us research program. All of Us is an initiative through partners of the National Black Nurses Association, which Fields is vice president of, and the National Institutes of Health that invites one million people across the U.S. to help build one of the most diverse health databases in U.S. history.

In this latest episode of the MHE Talks: Improving Patient Access series, Senior Editor Peter Wehrwein spoke with Dr. Christopher Crow, resident of Catalyst Health Network, a clinically integrated network of more than 1,000 primary care physicians throughout Texas. Peter and Dr. Crow discuss how his small-town roots and doctors there inspired his thinking about access issues; his experience with patient-centered medical homes and setting patient access as a priority; how Catalyst supports physicians in improving access; and the lack of Medicaid expansion in Texas and how that affects access there.